Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Wolfgang, Schmider"'
Autor:
Masanari Shiramoto, Tatsuya Yoshihara, Wolfgang Schmider, Hiroki Takagi, Irene Nowotny, Miyuki Kajiwara, Hideya Muto
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
Abstract This study compared the pharmacokinetic and glucodynamic profiles of biosimilar SAR341402 insulin aspart to Japan-approved insulin aspart (NovoRapid) in healthy Japanese males. In this single-center, randomized, double-blind, single-dose, tw
Externí odkaz:
https://doaj.org/article/91ffc0df4bcd43f98107227aa96b64ad
Autor:
Hiroki Takagi, Miyuki Kajiwara, Irene Nowotny, Masanari Shiramoto, Hideya Muto, Wolfgang Schmider, Tatsuya Yoshihara
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
Scientific Reports
Scientific Reports
This study compared the pharmacokinetic and glucodynamic profiles of biosimilar SAR341402 insulin aspart to Japan-approved insulin aspart (NovoRapid) in healthy Japanese males. In this single-center, randomized, double-blind, single-dose, two-period,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7b35348be8171f6c2a176b21c9b5311
https://doaj.org/article/91ffc0df4bcd43f98107227aa96b64ad
https://doaj.org/article/91ffc0df4bcd43f98107227aa96b64ad
Autor:
Viswanathan, Mohan, Wolfgang, Schmider, Kiran P, Singh, Baerbel, Rotthaeuser, Bhaswati, Mukherjee, S R, Aravind
Publikováno v:
Indian journal of endocrinology and metabolism. 26(4)
We compared the pharmacokinetic exposure, efficacy, safety and immunogenicity of biosimilar insulin aspart premix SAR341402 Mix 70/30 (SARThis was a randomized, open-label, parallel-group, substudy of the phase 3 GEMELLI M trial performed in three In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::907a679ad50e5ec5094be3eb23d0a403
https://pubmed.ncbi.nlm.nih.gov/36185965
https://pubmed.ncbi.nlm.nih.gov/36185965
Autor:
Wolfgang Schmider, Bhaswati Mukherjee, Christoph Kapitza, Lenore Teichert, Irene Nowotny, Leszek Nosek
Publikováno v:
Diabetes, Obesity and Metabolism. 23:674-681
AIM To compare the pharmacokinetic exposure of SAR341402 Mix 70/30 (SARAsp -Mix) with US- and European (EU)-approved versions of insulin aspart Mix 70/30 (NovoLog Mix 70/30 [NN-Mix-US]/NovoMix 30 [NN-Mix-EU]) and SAR341402 insulin aspart solution (SA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::78bdaafa2c988eb1e480252ceaa93718
https://doi.org/10.1111/dom.14260
https://doi.org/10.1111/dom.14260
Publikováno v:
Diabetes Technology & Therapeutics
Background: The objective of this study was to demonstrate the pharmacokinetic and pharmacodynamic similarity among SAR341402 insulin aspart biosimilar/follow-on product, United States-sourced insulin aspart (NovoLog®), and European Union-sourced in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::835b87dcd9ea09245d748d78b896ec2b
https://doi.org/10.1089/dia.2019.0351
https://doi.org/10.1089/dia.2019.0351
Autor:
Margarita Barrientos‐Pérez, Daniel S. Hsia, Lance Sloan, Haylene Nell, Ounisha Mungur, Lionel Hovsepian, Wolfgang Schmider, Robert Spranger, Na Yang, Elisabeth Niemoeller
Publikováno v:
Pediatric diabetesREFERENCES. 23(6)
The aim of this study was to investigate the pharmacokinetic, pharmacodynamic and safety profile of the glucagon-like peptide-1 receptor agonist, lixisenatide, for the treatment of type 2 diabetes (T2D) in pediatric individuals.In this Phase 1, multi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::263ecca8131ff32a72ef3d1d110de26e
https://pubmed.ncbi.nlm.nih.gov/35411611
https://pubmed.ncbi.nlm.nih.gov/35411611
Autor:
Masanari Shiramoto, Tatsuya Yoshihara, Wolfgang Schmider, Yoshinori Takahashi, Irene Nowotny, Miyuki Kajiwara, Hideya Muto
Publikováno v:
Clinical pharmacology in drug development. 11(6)
This phase 1 study compared the pharmacokinetic (PK) and glucose pharmacodynamic (PD) characteristics of biosimilar SAR342434 insulin lispro and Japan-reference Humalog insulin lispro. This was a randomized, double-blind, 2-period, crossover study. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1f731ffa9be950864cb320cb56d1ebd
https://pubmed.ncbi.nlm.nih.gov/35166054
https://pubmed.ncbi.nlm.nih.gov/35166054
Autor:
Christoph, Kapitza, Leszek, Nosek, Wolfgang, Schmider, Lenore, Teichert, Bhaswati, Mukherjee, Irene, Nowotny
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To compare the pharmacokinetic exposure of SAR341402 Mix 70/30 (SARAsp‐Mix) with US‐ and European (EU)‐approved versions of insulin aspart Mix 70/30 (NovoLog Mix 70/30 [NN‐Mix‐US]/NovoMix 30 [NN‐Mix‐EU]) and SAR341402 insulin aspart
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::33e0ce4f12209cf3aa62ea25b7bf8b21
https://pubmed.ncbi.nlm.nih.gov/33236518
https://pubmed.ncbi.nlm.nih.gov/33236518
Autor:
Anne Lehmann, Irene Nowotny, Leszek Nosek, Christoph Kapitza, Wolfgang Schmider, Baerbel Rotthaeuser
Publikováno v:
Diabetes. 68
SAR341402 (SAR-Asp), NovoLog (NN-Asp-US) and NovoRapid (NN-Asp-EU) are rapid-acting insulin aspart products. Exposure (PK) to and activity (PD) of SAR-Asp (T) NN-Asp-US (R1) and NN-Asp-EU (R2) were compared in a single-center, randomized, double-blin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51a453a2ceccf972f76d7b2904df51b7
https://doi.org/10.2337/db19-130-lb
https://doi.org/10.2337/db19-130-lb